Drug data last refreshed 21h ago · AI intelligence enriched 3w ago
ORTHO TRI-CYCLEN 21 is a combination oral contraceptive containing ethinyl estradiol and norgestimate in a 21-day tablet regimen. It prevents pregnancy through suppression of ovulation and alteration of cervical mucus and endometrium. This product is a mature, well-established hormonal contraceptive used by millions of women globally.
As an approaching LOE product, ORTHO TRI-CYCLEN 21 faces declining market exclusivity and margin pressure, signaling potential consolidation or transition of the brand team to line extensions or next-generation formulations.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on ORTHO TRI-CYCLEN 21 offers limited growth trajectory due to LOE approaching and minimal clinical pipeline activity. Career opportunities center on defensive brand management, generic competition mitigation, and customer access strategies rather than innovation or market expansion.
Worked on ORTHO TRI-CYCLEN 21 at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.